Published data shows that chemotherapy delivered via TAMP™ with prior chemoradiation in Locally Advanced Pancreatic Cancer (LAPC) observed an Overall Survival (OS) of 27-months Targeted chemotherapy delivery via TAMP is currently being evaluated in an ongoing Phase III clinical trial in LAPC LOS ALTOS, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local ...